Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Stuver

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Blood Advances|July 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysisNazila Shafagati, Min J Koh, Leora Boussi, et al.
Genes, Chromosomes & Cancer|August 12, 2024
A Novel JAK2 Fusion in T-Cell Prolymphocytic LeukemiaOzgur Can Eren, Robert Stuver, Ting Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
Haematologica|March 19, 2026
Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targetsRobert Stuver, Haiming Tang, Ahmet Dogan, et al.
Haematologica|November 27, 2025
Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomasKai Shiang Lin, Mingfei Yan, Nivetha Ganesan, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Blood Advances|January 13, 2022
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomasMin Jung Koh, Mwanasha H Merrill, Min Ji Koh, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Blood Advances|July 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysisNazila Shafagati, Min J Koh, Leora Boussi, et al.
Genes, Chromosomes & Cancer|August 12, 2024
A Novel JAK2 Fusion in T-Cell Prolymphocytic LeukemiaOzgur Can Eren, Robert Stuver, Ting Zhou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
Haematologica|March 19, 2026
Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targetsRobert Stuver, Haiming Tang, Ahmet Dogan, et al.
Haematologica|November 27, 2025
Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomasKai Shiang Lin, Mingfei Yan, Nivetha Ganesan, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Blood Advances|January 13, 2022
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomasMin Jung Koh, Mwanasha H Merrill, Min Ji Koh, et al.
Pageof 3